Metrogyl 200 Tablet contains Metronidazole 200 mg, an effective nitroimidazole antibiotic and antiprotozoal agent used primarily to treat anaerobic bacterial infections and protozoal diseases. It exhibits bactericidal activity by disrupting DNA synthesis in susceptible organisms, leading to cell death. Metrogyl 200 is indicated for the management of infections such as bacterial vaginosis, trichomoniasis, amoebiasis, giardiasis, and infections caused by anaerobic bacteria including intra-abdominal infections, skin and soft tissue infections, and respiratory tract infections. The tablet is typically administered orally, with dosage and duration tailored according to the severity and type of infection, as well as patient-specific factors. Common side effects may include nausea, metallic taste, headache, and gastrointestinal disturbances; patients are advised to avoid alcohol during treatment due to the risk of disulfiram-like reactions. Caution is warranted in patients with hepatic impairment or neurological disorders. Metrogyl 200 should be used under medical supervision to ensure appropriate use and to minimize the development of resistance. It is contraindicated in the first trimester of pregnancy and in patients with hypersensitivity to metronidazole or related compounds. Proper adherence to prescribed dosing regimens is essential for optimal therapeutic outcomes.